 |
Email the Society |
 |
Donations |
ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
Mailing address:
GPO Box 383,
Adelaide,
South Australia 5001
Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: (08) 8346 3237
('834 MECFS')
Office Hours:
Wednesdays, 10am-3pm
Support Line:
(Mondays and Thursdays,
10am-3pm)
Ph: (08) 8346 3237
SA country callers:
Ph: 1300 128 339
(local call)
FIBROMYALGIA HELP: Contact Fibromyalgia SA at the Arthritis Foundation of SA 118 Richmond Road, Marleston 5033 Ph: (08) 8379 5711 |
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
|
Disclaimer
ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
| Become a Member | |||
|
Findings by Reno scientists confirmed by U.S. government
Friday 20 August 2010
 Doctors Vince Lombardi, left, and Judy Mikovits stand talking in a laboratory inside the new Whittemore Peterson Institute for Neuro-Immune Disease at the School of Medicine on the UNR campus on August 16, 2010. (Andy Barron/RGJ) |
Findings by Reno scientists confirmed by U.S. government
Two Reno scientists, who last year discovered a new infectious human retrovirus they linked to Chronic Fatigue Syndrome, said Monday that their findings have been replicated and confirmed by the U.S. Food and Drug Administration.
Dr. Judy Mikovits, one of the lead researchers with the Whittemore Peterson Institute for Neuro-Immune Disease in Reno, said the FDA's review of their findings is scheduled to be published in September.
"There has been an issue over whether anybody could replicate our study, and it will not only confirm our findings but extend our findings, which is really exciting for us," she said.
Mikovits said they also have new, unpublished data concerning the retrovirus, XMRV, that could lead to treatment of Chronic Fatigue Syndrome.
"We have immune system profiles and we can tell by the immune system how the XMRV is doing the damage," she said. "So we could have a diagnostic test to follow clinical treatment and show that people's immune systems go back to normal. That's the latest data that's really amazing. That's what we're after."
That data will be published by the end of the year, probably in a clinical immunology journal, she said.
Lombardi said clinical trials could begin soon at the Whittemore Peterson Institute, which is relocating from its tiny laboratory on the University of Nevada, Reno campus to the university's newly opened Center for Molecular Medicine.
"Actually, we already have been contacted by people who are sending us tests, perceiving that they may be asked to be part of the clinical trials," he said.
"I think once the (FDA) paper comes out and once the controversy is put to rest, the pharmaceutical companies will realize that this is some very low-hanging fruit for them to make the next transition," said Lombardi. "There are so many drugs that have been developed for HIV, and it's a retrovirus. So there's probably a ton of HIV drugs that they can go back and re-screen that could be used."
There also are three published drugs that work against XMRV, Mikovits said.
"We totally expect at least one clinical treatment trial before the end of the year," she said. "That is our goal and that's what this new facility is for."
The article originally appeared here.
blog comments powered by Disqus
Previous Page |
